Skip to main content
Equibles
COGT logo

COGT · Cogent Biosciences, Inc.

Track COGT — free

Use COGT with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about COGT

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$36.72 -0.08 (-0.22%) At close · Aug 26
Market Cap
$6.39B
Shares
173.52M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$36.72 Open$36.49 Day$36.28–37.12 52W close$11.97–42.84 Avg vol 30d1.8M Short int18.4M · 10.6% float · 9.0d Short vol65% Last earningsMay 5, 2026 DataNov 2020–Aug 2026 Filing10-Q · Aug 10

Raw chart and full-history price indicators begin at the captured split on Nov 9, 2020; bars on opposite sides are not compared.

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 10, 2026

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Weak Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 15.2 · calm Equity put/call 0.64
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −0%
below
Price vs 50-day avg −5%
below
RSI (14) 44
neutral
MACD trend Negative
52-week position 80%
mid-range
Momentum
relative strength
Weak
1-month return −7%
trailing
6-month return −2%
trailing
YTD return +3%
this year
Relative strength −14%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $39 › 200d $37 — 50d above 200d
Institutional flow Accumulating
+6% holders QoQ · +66 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
10.61% of float · ▲ +2.9% MoM · 9.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
326 holders — near 3-yr high, broad support
Squeeze score 64
elevated · 0–100
Fundamentals
Weak
Revenue growth −65%
Y/Y
EPS growth −11%
Y/Y
Free cash flow $-266.0M
Balance sheet $312.0M
net cash
Quant / Vol
risk profile
Very High
Volatility 128%
annualized · 1-yr
Max drawdown −26%
past year
ATR 4.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
1 · 5 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−0% Neutral
Price vs 50-day avg
−5% Neutral
RSI (14)
44 Neutral
MACD trend
Negative Bearish
52-week position
80% Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $39 › 200d $37 — 50d above 200d
Institutional flow Accumulating
+6% holders QoQ · +66 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
10.61% of float · ▲ +2.9% MoM · 9.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
326 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $12 Now $37 · 80% Range high $43
vs 200-day avg 0% vs 50-day avg -5%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Pro forma cash balance $865.9M Q2 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
COGT
Cogent Biosciences, Inc.
this stock
$6.39B +3.4% -65.0% — 10.6%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $138.79B +20.7% +46.2% 31.9 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $83.89B +5.6% +20.8% 20.2 2.3%
ARGX
Argenx SE
 $63.81B +24.5% — — 1.9%
CSLLY
Csl Ltd
 $60.07B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
326
% held
112.5%
Net QoQ
+7.5M sh
Top holder
FMR LLC
Held Float
View
Held by Funds
Fund positions
361
View
Short & Settlement
Short Interest Rising
Shares short
18.4M
Days to cover
9.0d
Change
+518.0K sh
View
Short Volume
Short vol %
65%
As of
Aug 26, 2026
Short Total
View
Fails to Deliver
FTD shares
850
Value
$35.2K
As of
Jul 31, 2026
View
Off-Exchange
Off-exchange %
44.0%
Week of
Jul 20, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Buy
Member
Christopher L. Jacobs
Amount
$1.0K–$15.0K
Traded
Dec 12, 2022
View
Financials
Financials
Net income (FY)
$-328.9M
EPS diluted
$-2.16
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 10, 2026
This year
10
View
Proposed Sales
Value
$242.6M
Shares
7.0M
Filed
Mar 31, 2026
View
Exempt Offerings
Offering
$104.4M
Filed
Jul 21, 2020
View
Earnings & Events
Earnings Calls
Last call
Jun 3, 2026
View

Performance

Raw-price comparisons begin at the captured split on Nov 9, 2020; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
COGT -0.4% -7.2% -2.0% -5.7% +3.4%
SPY -0.4% +5.0% +12.4% +2.6% +12.3%
vs SPY +0.0% -12.2% -14.4% -8.2% -9.0%
Key facts CIK 1622229 CUSIP 19240Q201 13F (30d) 296 filings 294 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)